Replies to post #63027 on Biotech Values

[DewDiligence]

>ITMN – I found it interesting that on day 15 the study subjects will be given 1 dose of the study drug.<

What do you make of this quirk?

[DewDiligence]

>I think there is a good (50/50+) chance we see Roche initiate a study of some sort with a protease and polymerase late this year<

I agree. Roche is probably trying to decide whether to start with R1626 or R7128. They would naturally prefer the former but they will probably pick the latter.

[rkrw]

Do you think if telapravir is approved 191 will have to go head to head vs them? Could add a lot of time, cost and risk to pivotal studies. Also would it have to be non inferior or superior?